Stematix(TM) Attends Vatican Stem Cell Conference this Week.
Author: David F. Bonner
STEMATIX & BIODLOGICS SIGN EXCLUSIVE DISTRIBUTION AGREEMENT.
Author: Timmie Wang
Stematix Inc. has recently signed an exclusive distribution agreement with BioDlogics, a Memphis based biomedical company, to commercialize and distribute wound covering products derived from amniotic tissue. The agreement will encompass the territories of Argentina, Brazil, and Mexico. BioDlogics is an FDA registered tissue bank, which produces a line of amniotic-based wound covering products that are used to treat post-operative complications and a variety of other indications. The two primary products for distribution will be AmnioCare and AmnioGenesis.
Stematix Inc received a grant under the Qualifying Therapeutic Discovery Project (QTDP), for its clinical research program using AlloStrome™ cells
Author: Timmie Wang
Stematix™ Inc. is pleased to announce that it has been awarded a grant from the United States Internal Revenue Service, under the Qualifying Therapeutic Discovery Project (QTDP), for its clinical research program using AlloStrome™ cells.
Stematix received Ethical Committee approval to initiate a Clinical Trial using their proprietary Allostrome™ cells to improve patient outcomes after acute myocardial infarction.
Author: Timmie Wang
The Clinical Trial will be conducted at the Victoria General Hospital (Tamaulipas, Mx) under supervision of Dr. Américo Villarreal Anaya as Principal Investigator. Dr. Villarreal is a noted cardiologist. This Phase I/II study will be used to confirm pre-clinical data showing the beneficial anti-inflammatory role of Allostrome™ cells (bone marrow derived expanded mesenchymal stem cells) for the outcome of patients who had suffered an acute myocardial infarction.
Livers stripped bare of their original tissue then recoated with new cells have been successfully, for the first time, transplanted into rats and are functional as an organ.
Author: Timmie Wang
Orthotopic liver transplantation is the only available treatment for severe liver failure, but it is currently limited by organ shortage. One technical challenge that has thus far limited the development of a tissue-engineered liver graft is oxygen and nutrient transport. Here we demonstrate a novel approach to generate transplantable liver grafts using decellularized liver matrix. The decellularization process preserves the structural and functional characteristics of the native microvascular network, allowing efficient recellularization of the liver matrix with adult hepatocytes and subsequent perfusion for in vitro culture. The recellularized graft supports liver-specific function including albumin secretion, urea synthesis and cytochrome P450 expression at comparable levels to normal liver in vitro. The recellularized liver grafts can be transplanted into rats, supporting hepatocyte survival and function with minimal ischemic damage. These results provide a proof of principle for the generation of a transplantable liver graft as a potential treatment for liver disease.
Emerging Healthcare Solutions and Regenevita LLC begin good faith negotiations toward potential sub-license agreement for breakthrough stem cell technology
Author: Timmie Wang
Emerging Healthcare Solutions, Inc. (Pink Sheets:EHSI) announced today that the
Company has signed an option with Regenevita, owner of the right to license Neo Natal Progenitor Cell Expansion Technology in Latin America. The core technology on which the Regenevita LLC technology is based was originally developed by NASA, the National Aeronautics and Space Administration, and was sub-licensed to Regenevita for use with Neo Natal Progenitor Cell Expansion. The option begins a due diligence period for EHSI and also begins good faith negotiations between both parties with the intention of reaching a potential Sub-License Agreement. Regenevita LLC (www.regenevita.com) is a subsidiary of Stematix, Inc. (www.stematix.com), and is a joint venture between Stematix and EDCO Ventures (www.edcoonline.org) with a goal to establish pioneering leadership in regenerative medicine for the Rio Grande / Rio Bravo Valley. Regenevita believes it has a unique, sustainable cellular banking model that can facilitate the widespread use of regenerative cell therapy.
“We are very impressed with the leadership and development team of Regenevita. It is our belief they have the ability to emerge as world leaders in the advancement of stem cell technology and research,” stated Cindy Morrissey, President of EHSI. “Our participation in this deal has the potential to reap generous rewards for our company in both revenue and technological advancements.”
Former President of Argentina, Dr. Fernando de la Rua, visits Colorado stem cell therapy clinic: Regenexx™
Author: Timmie Wang
While in Denver, CO, to participate in the Transnational Summit of Former Heads of State with twelve other former Presidents, current government officials, and dignitaries during the Biennial of the Americas, the former Argentinean President, Dr. Fernando de la Rua, made a special trip to Broomfield, CO, yesterday to visit a stem cell therapy clinic. The visit, coordinated by David Bonner, Chairman & CEO of Stematix™, Inc., allowed Dr. De la Rua to tour the Centeno-Schultz Clinic, meet with the doctors and observe the Regenexx™ procedure performed on several patients.
